A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Conditions

• Hidradenitis Suppurativa

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Bimekizumab — DRUG
  Subjects will receive bimekizumab at pre-specified time-points.

Study Details

The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Key Dates

Start date

May 27, 2021

Status verified

Jun 2026

Primary completion

Jul 28, 2026

Completion

Jul 28, 2026

Study Design

Enrollment

658 participants (actual)

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Bimekizumab dosing regimen 1
  Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 during the open-label extension period.
• Experimental: Bimekizumab dosing regimen 2
  Subjects participating in the study will receive assigned bimekizumab dosing regimen 2 during the open-label extension period.

Primary Outcome Measure

Percentage of participants with treatment-emergent adverse events (TEAEs) during the study [ Time Frame: From Baseline (Day 1) until end of Safety Follow-Up (up to Week 196) ]

Locations (43)

Find similar trials in Birmingham, AL

Related Studies

• The Ohio State University Dermatology Biorepository
  Recruiting · Ohio State University · Columbus, Ohio
• Clinical and Biological Characteristics of Hidradenitis Suppurativa
  Recruiting · University of California, San Francisco · San Francisco, California
• Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository
  Recruiting · University of California, San Francisco · San Francisco, California
• Battlefield Acupuncture for Pain in Hidradenitis Suppurativa
  Recruiting · Wayne State University · Dearborn, Michigan